Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A

2(66.7%)

Phase 4

1(33.3%)

3Total

N/A(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05584189Not ApplicableCompleted

COVID-19 MP Biomedicals Rapid SARS-CoV-2 Antigen Test Usability

Role: lead

NCT05584176Not ApplicableCompleted

COVID-19 MP Biomedicals SARS-CoV-2 Ag OTC: Clinical Evaluation

Role: lead

NCT03226119Phase 4Completed

MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study

Role: lead

NCT03146013Completed

Dual Algorithm Post Market Clinical Study

Role: lead

NCT01467024Unknown

Evaluation of the MP Diagnostics HTLV Blot 2.4

Role: lead

All 5 trials loaded